

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LifeTech Scientific Corporation

先健科技公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1302)

SUPPLEMENTAL AGREEMENTS TO CERTAIN NEW TRANSACTION AGREEMENTS

Reference is made to the announcement of LifeTech Scientific Corporation (the “**Company**”) dated 28 July 2014 (the “**Announcement**”). Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the Announcement.

As disclosed in the Announcement, the Company and Medtronic, by themselves or through their Affiliates entered into the New Transaction Agreements on 25 July 2014 including the Cardiac Rhythm Device License Agreement and the Medical Lead License Agreement (collectively, the “**License Agreements**”), the Supply and Exclusive Distribution Agreement and the Equipment and Components Supply Agreement.

On 17 April 2015 (after trading hours), the parties entered into supplemental agreements in respect of (i) the License Agreements to revise the Perpetual Term of the License Agreements to a fixed term of 50 years; (ii) the Supply and Exclusive Distribution Agreement to revise the exhibit attached thereto for the specification of the products to be distributed; and (iii) the Equipment and Components Supply Agreement to revise the exhibit attached thereto for the specification of components to be supplied (collectively, the “**Revisions**”).

The Revisions were determined after further negotiations between the Company and Medtronic. The Directors consider that the Revisions are fair and reasonable, and the entering into of the aforementioned supplemental agreements is in the interests of the Company and the Shareholders as a whole.

Save and except for the aforesaid, all other terms and conditions of the License Agreements, the Supply and Exclusive Distribution Agreement and the Equipment and Components Supply Agreement including but not limited to the payment terms and the pricing mechanism as disclosed in the Announcement remain unchanged.

The Board wishes to update the Shareholders that in view of the above changes, the circular relating to the New Transaction Agreements will also include details of the Revisions, and will be despatched on or before 30 April 2015 as previously disclosed in the Company's announcement dated 16 March 2015.

By order of the Board
LifeTech Scientific Corporation
XIE Yuehui
*Chairman, Chief Executive Officer
and Executive Director*

Hong Kong, 17 April 2015

As at the date of this announcement, the Board comprises Mr. XIE Yuehui and Mr. LIU Jianxiong being executive Directors of the Company; Mr. WU Jianhui, Mr. MARTHA Geoffrey Straub, Mr. MONAGHAN Shawn Del and Mr. JIANG Feng being non-executive Directors of the Company; and Mr. LIANG Hsien Tse Joseph, Mr. ZHOU Luming and Mr. ZHOU Gengshen being independent non-executive Directors of the Company.